The Atherogenic Index of Plasma（AIP） in Patients With Atrial Fibrillation

Cardiovascular Diseases Clinical Trial

Official title:

Prognostic Value of the Atherogenic Index of Plasma（AIP）for Cardiovascular Outcomes in Patients With Atrial Fibrillation

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05973474
• Other study ID #: SYSKY-2023-634-01
• Status: Not yet recruiting
• Start date: July 30, 2023
• Est. completion date: July 2024

Study information

• Verified date: July 2023
• Source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to learn about The Atherogenic Index of Plasma(AIP) in patients with atrial fibrillation(AF). The main questions it aims to answer are: (1)To investigate the correlation between AIP and the occurrence rate of AF. (2) To investigate the correlation between AIP and the occurrence rate of cardiovascular outcome events (MACE events, heart failure, embolism events) in patients with AF. Patients's clinical data including medical history, laboratory tests, and imageological examination will be collected and further analysed.

Description:

Baseline demographic data: age, gender, height, weight, systolic blood pressure, diastolic blood pressure, smoking habit, drinking habit, physical activity, fasting blood glucose, medication use (statins, ACEI/ARB, anticoagulant related drugs), basic medical history (hypertension, diabetes mellitus, coronary heart disease).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 5000
• Est. completion date: July 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Atrial fibrillation was detected by electrocardiogram or 24-hour holter or portable electrocardiogram monitor;

2. age =18 years old;

3. "low-intermediate" risk group of AF cardioembolic stroke: male patients with CHA2DS2-VASc score 0-1 or female patients with CHA2DS2-VASc score 1-2

Exclusion Criteria:

1. patients with rheumatic heart disease, congenital heart disease, cardiomyopathy, hematological diseases, severe hepatic and renal insufficiency and connective tissue diseases;

2. Echocardiography showed valvular heart disease;

3. patients with transient atrial fibrillation secondary to reversible causes:

hyperthyroidism, acute pulmonary embolism, recent surgery, acute myocardial infarction, etc.

4. severe carotid artery stenosis and intracranial artery stenosis;

5. AF patients with recent major surgery.

6. patients with serious lack of clinical data.

Related Conditions & MeSH terms

• Atrial Fibrillation
• Atrium; Fibrillation
• Cardiovascular Diseases
• Lipid Metabolism Disorders
• Metabolic Diseases

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	atrial fibrillation (AF)	AF diagnoses were ascertained by 3 different sources in our study: ECGs performed at study visits, hospital discharge codes, and death certificates. All ECGs automatically coded as AF were visually checked by a trained cardiologist to confirm AF diagnosis.	10 years
Secondary	major adverse cardiovascular events (MACEs)	Follow up main adverse cardiovascular and cerebrovascular events such as death, myocardial infarction, stroke, and repeated revascularization.	10 years
Secondary	heart failure	Patients who required intravenous medications for heart failure after admission (including diuretics, vasodilators, or inotropic agents) or a significant increase in the dose of oral diuretics (i.e., an increase in furosemide of =40mg or equivalent or the addition of a thiazide to a loop diuretic) were considered to have heart failure readmission. Pulmonary rales and/or the third heart sound, chest X-ray, dyspnea, peripheral edema, and NYHA grade were evaluated to further confirm the occurrence of heart failure.	10 years